A Phase 3 interventional study of Emicizumab in Hemophilia A, sponsored by Hoffmann-La Roche. Completed at 17 sites in 6 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-01-11.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing emicizumab in Hemophilia A — 6 open to participants now, 8 under way, 3 of them phase 3. emicizumab · Hemophilia A.
Among the 22 studies testing emicizumab in Hemophilia A, this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 3, and was the 4th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →6 of the 22 studies testing emicizumab in Hemophilia A are open now, in 4 countries. Recruiting first, the newest first:
Sanofi · Sites in United States, Taiwan
Ages 12+ · Men only
Chulalongkorn University · Sites in Thailand
Ages 3–30 · Men only · Healthy volunteers
Bleeding and Clotting Disorders Institute Peoria, Illinois · Sites in United States
Ages 0–90
Indiana Hemophilia &Thrombosis Center, Inc. · Sites in United States
Ages 5–45 · Men only
Versiti Blood Health · Sites in United States
Ages 0–17
By country, each count listing its studies:
emicizumab: first FDA approval 2017 (HEMLIBRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 2 · Phase 3 13 · Phase 4 6
First in 2015; this study’s year is marked. 2 started in 2017.
This study's enrollment of 48 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 27 across the 22 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 22 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
25 studies in Hemophilia A by Hoffmann-La Roche: 5 open now, 8 under way, 4 of them phase 3. Of 15 finished, 12 (80%) have results posted.
Among the 25 studies in Hemophilia A by Hoffmann-La Roche, this one is the 13th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2017, is one of 12 in phase 3, and was the 7th registered.
Hoffmann-La Roche’s Hemophilia A studies by the year they started, since 2012.
2 of the studies testing emicizumab in Hemophilia A that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05181618Hoffmann-La RocheA Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis | 2026-11-19 |
| NCT05500807Bleeding and Clotting Disorders Institute Peoria, IllinoisEmicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing emicizumab in Hemophilia A, from their registry updates:
Among Hoffmann-La Roche’s 25 in Hemophilia A:
This tab as a report to print or save as PDF → With an account.
This multicenter, open-label, non-randomized study will assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg/kg) every 4 weeks in participants with hemophilia A with or without inhibitors against factor VIII (FVIII). The study consists of 2 parts: a pharmacokinetic (PK) run-in part followed by an expansion part.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received emicizumab subcutaneously (SC) at a dose of 6 mg/kg once every 4 weeks, with no loading dose, for at least 24 weeks.
Drug: Emicizumab
Participants received emicizumab subcutaneously (SC) at a loading dose of 3 mg/kg once every week for the first 4 weeks followed by a maintenance dose of 6 mg/kg emicizumab SC once every 4 weeks for at least 24 weeks.
Drug: Emicizumab
Emicizumab will be administered according to dose and schedule described in respective arms. After at least 24 weeks on prophylactic emicizumab, individuals who experienced suboptimal bleeding control on emicizumab (according to protocol-defined criteria) had the opportunity to increase their dose to 3 mg/kg weekly. Upon implementation of protocol Version 5 (20-Dec-2019), treatment duration was extended. During this study prolongation, participants had the opportunity to switch to a preferred emicizumab dosing regimen (1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks) in order to provide them the same flexibility as with commercial product.
Also known as: Hemlibra, RO5534262, ACE910
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds
The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.
Time frame: From Baseline to at least 24 weeks
Expansion Part: Annualized Bleeding Rate (ABR) for All Bleeds
The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the "treated bleeds" outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
Time frame: From Baseline to at least 24 weeks
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds
The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.
Time frame: From Baseline to at least 24 weeks
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Joint Bleeds
The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "joint bleed" is defined as a bleed with type reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A "treated joint bleed" is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of joint bleeds, excluding bleeds due to surgery/procedure.
Time frame: From Baseline to at least 24 weeks
Expansion Part: Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds
The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "target joint bleed" is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A "treated target joint bleed" is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.
Time frame: From Baseline to at least 24 weeks
Expansion Part: Change From Baseline to Week 25 in the Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Total Score for Adult Participants (≥18 Years of Age)
The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.
Time frame: Baseline, Week 25
Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Total Score
The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.
Time frame: Baseline, Week 25
Expansion Part: Change From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score for Adult Participants (≥18 Years of Age)
The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.
Time frame: Baseline, Week 25
Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score
The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.
Time frame: Baseline, Week 25
Expansion Part: Change From Baseline to Week 25 in the Hemophilia-Quality of Life-Short Form (Haemo-QoL-SF) Questionnaire Total Score for Adolescent Participants (12-17 Years of Age)
The Haemo-QoL-SF was developed in a series of age-related questionnaires to measure health-related quality of life (HRQoL) in children and adolescents with hemophilia. The short version for older children containing 35 items was selected for adolescents in this study. Items are rated along five response options: never, rarely, sometimes, often, or all the time. This version covers nine dimensions considered relevant for the children's HRQoL (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia, and treatment). Scale scores range from 0 to 100, with lower scores indicating better HRQoL. Given the small number of adolescent participants, the results of the Haemo-QoL-SF questionnaire should be interpreted with caution.
Time frame: Baseline, Week 25
Expansion Part: Change From Baseline to Week 25 in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.
Time frame: Baseline, Week 25
Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire VAS Score
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.
Time frame: Baseline, Week 25
Expansion Part: Change From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.
Time frame: Baseline, Week 25
Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.
Time frame: Baseline, Week 25
Expansion Part: Proportion of Days Away From Work to Expected Days at Work in the Previous Four Weeks
Participants enrolled in the expansion part of the study reported at each time point the number of days away from work (i.e., days of work missed) and the expected number of days at work in the previous four weeks, which is reported here for each time point as the proportion of the number of days away from work to the expected number of days at work.
Time frame: Predose at Baseline, Weeks 13 and 25
Expansion Part: Proportion of Days Away From School to Expected Days at School in the Previous Four Weeks
Participants enrolled in the expansion part of the study reported at each time point the number of days away from school (i.e., days of school missed) and the expected number of days at school in the previous four weeks, which is reported here as the proportion of the number of days away from school to the expected number of days at school.
Time frame: Predose at Baseline, Weeks 13 and 25
Expansion Part: Number of Days Hospitalized
Time frame: From Baseline until at least 24 weeks of treatment (median [min-max] observation time: 25.57 [24.1-29.4] weeks)
Expansion Part: Percentage of Participants Who Preferred Either the New Emicizumab Subcutaneous (SC) Treatment or Their Previous Hemophilia Intravenous (IV) Treatment, or Had No Preference, as Assessed Using the Emicizumab Preference Survey
The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with intravenous (IV) factor VIIII (FVIII) or subcutaneous (SC) emicizumab, or no preference.
Time frame: Predose at Week 17
PK Run-In Part: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Emicizumab
Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
PK Run-In Part: Maximum Observed Plasma Concentration (Cmax) of Emicizumab
Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
PK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to End of Dosing Interval (AUC[0-tau]) of Emicizumab
Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
PK Run-In Part: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Emicizumab
Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
PK Run-In Part: Apparent Plasma Terminal Half-Life (t1/2) of Emicizumab
Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
PK Run-In Part: Apparent Clearance (CL/F) of Emicizumab
Only CL/F is reported after the first dose; the apparent clearance at steady state (CLss/F) is reported after the sixth dose instead. This is because t1/2 was not properly estimated after the first dose due to sampling time and dosing schedule, and dependent PK parameters, such as CL/F, could not be estimated.
Time frame: Week 1 Day 1 predose (0 hours) and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 21, 22, 23, 24, and 25
PK Run-In Part: Plasma Concentration of Emicizumab at Specified Timepoints
Time frame: Week 1 Day 1 predose and 8 hours postdose, and Week 1 Days 3 and 5, Week 2 Days 8 and 11, Week 3 Days 15 and 18, Week 4 Days 22 and 25, and Day 1 of Weeks 5, 6, 7, 8, 9, 11, 13, 15, 17, 19, 21, 22, 23, 24, and 25, and every 12 weeks thereafter to Week 265
Expansion Part: Plasma Concentration of Emicizumab at Specified Timepoints
Time frame: Predose at Weeks 1, 2, 3, 4, 5, 9, 13, 17, 21, 25, 37, 49, 61, 73. 85, 97, 109, 121, 133, 145, 157, 169, 181, 193, 205, 217, 229, 241, and 253
Number of Participants With at Least One Adverse Event
The number of participants experiencing at least one adverse event (AE), including all non-serious and serious AEs, is reported here. According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to the World Health Organization \[WHO\] toxicity grading scale); the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Grade ≥3 Adverse Event
The World Health Organization (WHO) Toxicity Grading Scale was used for assessing adverse event (AE) severity. For AEs that are not specifically listed in the WHO Toxicity Grading Scale, a Grade 3 AE is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a Grade 4 AE is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE; the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment
According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to the World Health Organization \[WHO\] toxicity grading scale); the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Adverse Event Related to Study Treatment
According to the ICH guideline for Good Clinical Practice, an adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. In order to assess the causality of an AE, investigators used their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating "yes" or "no" accordingly.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Adverse Event of Changes From Baseline in Vital Signs
The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. All of the adverse events reported here were assessed independently by the investigator as not related to treatment with emicizumab.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings
Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Shift in Clinical Laboratory Parameters From Baseline World Health Organization (WHO) Toxicity Scale Grade 0-2 to Post-Baseline WHO Grade 3 or 4
An abnormal laboratory value was defined as a laboratory test result outside of the normal range for hematology or serum chemistry parameters. The WHO toxicity grading scale, which ranges from Grades 1 to 4 (least severe to most severe, respectively; Grade 0 is within normal range), was used for assessing the severity of laboratory abnormalities and adverse events (WHO 2003). Not every laboratory abnormality qualified as an adverse event; an abnormality was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. In this study, any laboratory value changes were transient and returned to baseline for all participants.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Local Injection-Site Reaction
Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an "injection-site reaction" on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a "local injection-site reaction."
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Thromboembolic Event
Hypercoagulation and thromboembolic events were to be reported as serious adverse events or adverse events of special interest. Healthcare providers educated patients/caregivers to recognize the signs and symptoms of potential thromboembolism (i.e., dyspnea, chest pain, leg pain or swelling, etc.) and to ensure that they understood the importance of seeking appropriate medical attention.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Thrombotic Microangiopathy
Thrombotic microangiopathy is used to describe a group of disorders with clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys, gastrointestinal system, or central nervous system, etc. Thrombotic microangiopathy events were to be reported as serious adverse events or adverse events of special interest.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction
Since emicizumab is a biological product, acute, systemic hypersensitivity reactions, including anaphylaxis and anaphylactic reactions, may occur. These events were to be reported as serious adverse events or adverse events of special interest. Healthcare providers (HCP) instructed patients and caregivers how to recognize the signs and symptoms of hypersensitivity, anaphylactic, and anaphylactoid reactions and to contact an HCP or seek emergency care in case of any such occurrence.
Time frame: From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months)
Number of Participants With Anti-Drug Antibodies to Emicizumab at Any Time Post-Baseline During the Study
A validated enzyme-linked immunosorbent assay (ELISA) method was used to analyze the levels of anti-drug antibodies (ADAs) to emicizumab in blood plasma samples. Participants were considered ADA-positive if they were ADA-negative at baseline but developed an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater (i.e., ≥ 0.60 titer units) than the titer of the baseline sample (treatment-enhanced ADA response).
Time frame: Baseline, Weeks 5, 9, 13, 17, 21, and 25, and every 12 weeks thereafter until study completion (up to 5 years, 5 months)
Number of Participants With De Novo Development of Anti-Factor VIII (FVIII) Antibodies
The levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold.
Time frame: Baseline, Weeks 9 and 17 (for non-inhibitor subjects only), Week 25, and every 12 weeks thereafter until study completion (up to 5 years, 5 months)
Long-Term Efficacy of Emicizumab: Model-Based Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds
The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds, All Bleeds, Treated Spontaneous Bleeds, Treated Joint Bleeds, and Treated Target Joint Bleeds
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
Time frame: From start of emicizumab treatment to study completion, dose up-titration, or change of dosing regimen (median [min-max] efficacy period for all emicizumab participants: 191.14 [28.0-264.4] weeks)
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Bleeds Per 12-Week Intervals Over Time
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for All Bleeds Per 12-Week Intervals Over Time
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Long-Term Efficacy of Emicizumab: Mean Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
Long-Term Efficacy of Emicizumab: Median Calculated Annualized Bleeding Rates (ABR) for Treated Spontaneous Bleeds Per 12-Week Intervals Over Time
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
Time frame: 1-12, 13-24, 25-36, 37-48, 49-60, 61-72, 73-84, 85-96, 97-108, 109-120, 121-132, 133-144, 145-156, 157-168, 169-180, 181-192, 193-204, 205-216, 217-228, 229-240, 241-252, and 253-264 weeks
| Milestone | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Started | 7 | 41 |
| Completed 24 weeks in the study | 7 | 41 |
| Emicizumab dose was up-titrated | 0 | 4 |
| Opted for a change in emicizumab dosing regimen | 0 | 1 |
| Completed | 6 | 41 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times. A bleed is considered a "treated bleed" if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a "treatment for bleed", irrespective of time between treatment and the preceding bleed. A bleed and the first treatment thereafter and before a new bleed starts, are considered to be pairs, with the following exception: if multiple bleeds occur on the same calendar day, the subsequent treatment is considered to apply for each of these multiple bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location are counted as one bleed if the second bleed occurs within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure are excluded.
| treated bleed rate per year | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Annualized Bleeding Rate (ABR) for Treated Bleeds | 2.4 (1.38 to 4.28) |
The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule was implemented exactly as defined for the "treated bleeds" outcome measure. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.
| all bleed rate per year | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Annualized Bleeding Rate (ABR) for All Bleeds | 4.5 (3.10 to 6.60) |
The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A bleed is classified as "spontaneous" if there is no other known contributing factor such as trauma or procedure/surgery. A "treated spontaneous bleed" is a spontaneous bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of spontaneous bleeds. Bleeds due to surgery/procedure are excluded.
| treated spontaneous bleed rate per year | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds | 0.6 (0.27 to 1.53) |
The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "joint bleed" is defined as a bleed with type reported as "joint" and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. A "treated joint bleed" is a joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Treated bleeds that fulfilled the 72-hour rule were included in the analysis of joint bleeds, excluding bleeds due to surgery/procedure.
| treated joint bleed rate per year | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Annualized Bleeding Rate (ABR) for Treated Joint Bleeds | 1.7 (0.82 to 3.68) |
The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was analyzed using a negative binomial regression model with efficacy period as an offset to account for the difference in follow-up times (i.e., the time that each participant stays in the study). A "target joint bleed" is defined as a joint bleed in a target joint, which is a joint location where at least 3 bleeds have occurred over the last 24 weeks prior to study entry. A "treated target joint bleed" is a target joint bleed that also fulfills the conditions of a treated bleed (see ABR for Treated Bleeds for the definition). Bleeds due to surgery/procedure are excluded.
| treated target joint bleed rate per year | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds | 1.0 (0.31 to 3.26) |
The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.
| units on a scale | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Change From Baseline to Week 25 in the Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Total Score for Adult Participants (≥18 Years of Age) | -13.62 (-18.36 to -8.88) |
The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 7 points or more on the Total Score was defined as the threshold for a clinically meaningful improvement.
| percentage of participants | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Total Score | 67.6 |
The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.
| units on a scale | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Change From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score for Adult Participants (≥18 Years of Age) | -15.14 (-22.44 to -7.83) |
The Haem-A-QoL is a patient-reported questionnaire that was designed for adult participants with hemophilia. It consists of 46 items comprising 10 dimensions (physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feelings, relationships, treatment, view of yourself, and outlook for the future) and a scale representing Total Score. Items are rated along five response options: never, rarely, sometimes, often, or all the time; although for some items there is also a "not applicable" option. Scale scores range from 0 to 100 with lower scores reflective of better quality of life. A decrease of 10 points or more on the Physical Health Score was defined as the threshold for a clinically meaningful improvement.
| percentage of participants | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Percentage of Adult Participants (≥18 Years of Age) With a Clinically Meaningful Improvement From Baseline to Week 25 in the Haem-A-QoL Questionnaire Physical Health Score | 67.6 |
The Haemo-QoL-SF was developed in a series of age-related questionnaires to measure health-related quality of life (HRQoL) in children and adolescents with hemophilia. The short version for older children containing 35 items was selected for adolescents in this study. Items are rated along five response options: never, rarely, sometimes, often, or all the time. This version covers nine dimensions considered relevant for the children's HRQoL (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia, and treatment). Scale scores range from 0 to 100, with lower scores indicating better HRQoL. Given the small number of adolescent participants, the results of the Haemo-QoL-SF questionnaire should be interpreted with caution.
| units on a scale | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Change From Baseline to Week 25 in the Hemophilia-Quality of Life-Short Form (Haemo-QoL-SF) Questionnaire Total Score for Adolescent Participants (12-17 Years of Age) | -8.10 ± 6.48 |
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.
| units on a scale | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Change From Baseline to Week 25 in the European Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score | 5.53 (1.15 to 9.90) |
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. An increase in the VAS score of 7 points or greater was defined as the threshold for a meaningful improvement.
| percentage of participants | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire VAS Score | 35.0 |
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.
| units on a scale | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Change From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score | 0.06 (0.03 to 0.10) |
The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. Published weighting systems allow for creation of a single summary score for the Index Utility Score where overall scores range from 0 to 1, with lower scores representing a higher level of dysfunction. An increase in the Index Utility Score of 0.07 points or greater was defined as the threshold for a meaningful improvement.
| percentage of participants | Emicizumab: Expansion Cohort |
|---|---|
| Expansion Part: Percentage of Participants With a Meaningful Improvement From Baseline to Week 25 in the EQ-5D-5L Questionnaire Index Utility Score | 47.5 |
Participants enrolled in the expansion part of the study reported at each time point the number of days away from work (i.e., days of work missed) and the expected number of days at work in the previous four weeks, which is reported here for each time point as the proportion of the number of days away from work to the expected number of days at work.
| away/expected work days | Emicizumab: Expansion Cohort |
|---|---|
| Baseline | 0.05 (0.01 to 0.10) |
| Week 13 | 0.00 (0.00 to 0.00) |
| Week 25 | 0.01 (0.00 to 0.02) |
Participants enrolled in the expansion part of the study reported at each time point the number of days away from school (i.e., days of school missed) and the expected number of days at school in the previous four weeks, which is reported here as the proportion of the number of days away from school to the expected number of days at school.
| away/expected school days | Emicizumab: Expansion Cohort |
|---|---|
| Baseline | 0.12 (0.01 to 0.24) |
| Week 13 | 0.00 (0.00 to 0.00) |
| Week 25 | 0.03 (0.00 to 0.10) |
| days | Emicizumab: PK Run-In Cohort |
|---|---|
| Expansion Part: Number of Days Hospitalized | 0 ± 0 |
The Emicizumab Preference Survey is a fit-for-purpose questionnaire developed by the sponsor to record the participant's preference for treatment with intravenous (IV) factor VIIII (FVIII) or subcutaneous (SC) emicizumab, or no preference.
| percentage of participants | Emicizumab: PK Run-In Cohort |
|---|---|
| Prefer the New Emicizumab SC Treatment | 100 (91.40 to 100.00) |
| Prefer My Old Hemophilia Treatment (IV) | 0.0 (0.00 to 8.60) |
| Have No Preference | 0.0 (0.00 to 8.60) |
| day | Emicizumab: PK Run-In Cohort |
|---|---|
| After First Dose (Weeks 1-5) | 6.95 (3.99 to 7.18) |
| After Sixth Dose (Weeks 21-25) | 6.98 (6.90 to 14.03) |
| μg/mL | Emicizumab: PK Run-In Cohort |
|---|---|
| After First Dose (Weeks 1-5) | 31.8 ± 19.3 |
| After Sixth Dose (Weeks 21-25) | 62.7 ± 17.3 |
| day*μg/mL | Emicizumab: PK Run-In Cohort |
|---|---|
| After First Dose (Weeks 1-5) | 663 ± 19.6 |
| After Sixth Dose (Weeks 21-25) | 1420 ± 20.7 |
| day*μg/mL | Emicizumab: PK Run-In Cohort |
|---|---|
| After First Dose (Weeks 1-5) | 1490 ± 27.2 |
| day | Emicizumab: PK Run-In Cohort |
|---|---|
| After First Dose (Weeks 1-5) | 29.5 ± 38.5 |
Only CL/F is reported after the first dose; the apparent clearance at steady state (CLss/F) is reported after the sixth dose instead. This is because t1/2 was not properly estimated after the first dose due to sampling time and dosing schedule, and dependent PK parameters, such as CL/F, could not be estimated.
| mL/h | Emicizumab: PK Run-In Cohort |
|---|---|
| After First Dose (Weeks 1-5) | 10.7 ± 23.9 |
| After Sixth Dose (Weeks 21-25) | 11.1 ± 20.8 |
| μg/mL | Emicizumab: PK Run-In Cohort |
|---|---|
| Week 1, Day 1 - Predose | NA ± NA |
| Week 1, Day 1 - 8 hours | 7.0 ± 71.7 |
| Week 1, Day 3 | 20.6 ± 51.2 |
| Week 1, Day 5 | 26.5 ± 29.7 |
| Week 2, Day 8 | 29.4 ± 25.1 |
| Week 2, Day 11 | 27.7 ± 21.9 |
| Week 3, Day 15 | 26.3 ± 20.5 |
| Week 3, Day 18 | 24.1 ± 21.6 |
| Week 4, Day 22 | 22.0 ± 14.8 |
| Week 4, Day 25 | 20.6 ± 15.6 |
| Week 5 | 18.5 ± 18.2 |
| Week 6 | 47.4 ± 13.8 |
| Week 7 | 42.1 ± 18.3 |
| Week 8 | 35.4 ± 22.5 |
| Week 9 | 28.2 ± 18.6 |
| Week 11 | 55.9 ± 20.4 |
| Week 13 | 34.6 ± 24.1 |
| Week 15 | 52.0 ± 17.0 |
| Week 17 | 36.7 ± 16.1 |
| Week 19 | 50.8 ± 32.6 |
| Week 21 | 34.5 ± 25.1 |
| Week 22 | 62.2 ± 17.5 |
| Week 23 | 56.5 ± 19.0 |
| Week 24 | 47.9 ± 28.7 |
| Week 25 | 39.2 ± 25.3 |
| Week 37 | 34.0 ± 15.8 |
| Week 49 | 34.7 ± 23.2 |
| Week 61 | 41.1 ± 25.9 |
| Week 73 | 39.7 ± 22.8 |
| Week 85 | 38.0 ± 29.2 |
| Week 97 | 43.6 ± 17.1 |
| Week 109 | 37.7 ± 13.8 |
| Week 121 | 39.6 ± 19.8 |
| Week 133 | 37.5 ± 14.2 |
| Week 145 | 34.8 ± 13.1 |
| Week 157 | 35.0 ± 20.7 |
| Week 181 | 45.4 ± 14.6 |
| Week 193 | 37.9 ± 21.5 |
| Week 205 | 45.4 ± 21.0 |
| Week 217 | 45.3 ± 11.3 |
| Week 229 | 52.1 ± 18.6 |
| Week 241 | 45.6 ± 13.6 |
| Week 253 | 40.4 ± 13.8 |
| Week 265 | 42.4 ± 16.5 |
| μg/mL | Emicizumab: Expansion Cohort |
|---|---|
| Week 1 | NA ± NA |
| Week 2 | 16.0 ± 36.8 |
| Week 3 | 29.8 ± 30.5 |
| Week 4 | 41.3 ± 32.4 |
| Week 5 | 48.8 ± 32.2 |
| Week 9 | 40.4 ± 45.7 |
| Week 13 | 38.9 ± 49.1 |
| Week 17 | 36.1 ± 53.8 |
| Week 21 | 37.4 ± 48.3 |
| Week 25 | 37.6 ± 52.5 |
| Week 37 | 39.6 ± 49.9 |
| Week 49 | 40.2 ± 48.4 |
| Week 61 | 38.7 ± 51.7 |
| Week 73 | 42.1 ± 51.2 |
| Week 85 | 36.4 ± 50.8 |
| Week 97 | 35.6 ± 49.5 |
| Week 109 | 33.0 ± 63.6 |
| Week 121 | 32.5 ± 60.5 |
| Week 133 | 33.7 ± 49.0 |
| Week 145 | 36.5 ± 51.7 |
| Week 157 | 47.3 ± 36.0 |
| Week 169 | 41.7 ± 41.9 |
| Week 181 | 45.1 ± 47.9 |
| Week 193 | 48.6 ± 47.0 |
| Week 205 | 46.0 ± 48.2 |
| Week 217 | 43.9 ± 47.8 |
| Week 229 | 50.2 ± 43.1 |
| Week 241 | 36.2 ± 46.5 |
| Week 253 | 38.8 ± 46.6 |
The number of participants experiencing at least one adverse event (AE), including all non-serious and serious AEs, is reported here. According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to the World Health Organization \[WHO\] toxicity grading scale); the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Any Adverse Event (AE) | 7 | 39 |
| Serious AE | 2 | 8 |
The World Health Organization (WHO) Toxicity Grading Scale was used for assessing adverse event (AE) severity. For AEs that are not specifically listed in the WHO Toxicity Grading Scale, a Grade 3 AE is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a Grade 4 AE is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE; the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With at Least One Grade ≥3 Adverse Event | 2 | 7 |
According to the ICH guideline for Good Clinical Practice, an AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. The terms "severe" and "serious" are not synonymous. A serious AE is any AE that is a significant medical event meeting any of the standard criteria. Severity refers to the intensity of an AE (e.g., rated as mild, moderate, or severe, or according to the World Health Organization \[WHO\] toxicity grading scale); the event itself may be of relatively minor medical significance. Severity and seriousness were independently assessed by the investigator for each reported AE.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With at Least One Adverse Event Leading to Withdrawal From Treatment | 0 | 0 |
According to the ICH guideline for Good Clinical Practice, an adverse event (AE) is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product, regardless of causal attribution. In order to assess the causality of an AE, investigators used their knowledge of the patient, the circumstances surrounding the event, and an evaluation of any potential alternative causes to determine whether an AE is considered to be related to the study drug, indicating "yes" or "no" accordingly.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Any Adverse Event Related to Study Treatment | 2 | 14 |
| Injection Site Reaction | 1 | 9 |
| Chills | 0 | 1 |
| Presyncope | 0 | 1 |
| Rash | 0 | 1 |
| Erythema | 0 | 1 |
| Incorrect Dose Administered | 0 | 1 |
| Accidental Overdose | 0 | 1 |
| Iron Deficiency Anaemia | 1 | 0 |
The number of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. All of the adverse events reported here were assessed independently by the investigator as not related to treatment with emicizumab.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Hypertension | 2 | 4 |
| Pyrexia | 1 | 4 |
| Tachycardia | 0 | 1 |
Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With at Least One Adverse Event of Changes From Baseline in Physical Examination Findings | 0 | 0 |
An abnormal laboratory value was defined as a laboratory test result outside of the normal range for hematology or serum chemistry parameters. The WHO toxicity grading scale, which ranges from Grades 1 to 4 (least severe to most severe, respectively; Grade 0 is within normal range), was used for assessing the severity of laboratory abnormalities and adverse events (WHO 2003). Not every laboratory abnormality qualified as an adverse event; an abnormality was reported as an adverse event if it met any of the following criteria: was accompanied by clinical symptoms; resulted in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); resulted in a medical intervention or a change in concomitant therapy; or was clinically significant in the investigator's judgment. In this study, any laboratory value changes were transient and returned to baseline for all participants.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Aspartate Aminotransferase (AST) - High | 0 | 1 |
| Calcium, Corrected - Low | 0 | 1 |
| Phosphorus - Low | 0 | 2 |
| Sodium - High | 0 | 1 |
Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an "injection-site reaction" on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a "local injection-site reaction."
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With at Least One Local Injection-Site Reaction | 1 | 9 |
Hypercoagulation and thromboembolic events were to be reported as serious adverse events or adverse events of special interest. Healthcare providers educated patients/caregivers to recognize the signs and symptoms of potential thromboembolism (i.e., dyspnea, chest pain, leg pain or swelling, etc.) and to ensure that they understood the importance of seeking appropriate medical attention.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With at Least One Thromboembolic Event | 0 | 0 |
Thrombotic microangiopathy is used to describe a group of disorders with clinical features of microangiopathic hemolytic anemia, thrombocytopenia, and organ damage that can include the kidneys, gastrointestinal system, or central nervous system, etc. Thrombotic microangiopathy events were to be reported as serious adverse events or adverse events of special interest.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With at Least One Thrombotic Microangiopathy | 0 | 0 |
Since emicizumab is a biological product, acute, systemic hypersensitivity reactions, including anaphylaxis and anaphylactic reactions, may occur. These events were to be reported as serious adverse events or adverse events of special interest. Healthcare providers (HCP) instructed patients and caregivers how to recognize the signs and symptoms of hypersensitivity, anaphylactic, and anaphylactoid reactions and to contact an HCP or seek emergency care in case of any such occurrence.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With at Least One Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reaction | 0 | 0 |
A validated enzyme-linked immunosorbent assay (ELISA) method was used to analyze the levels of anti-drug antibodies (ADAs) to emicizumab in blood plasma samples. Participants were considered ADA-positive if they were ADA-negative at baseline but developed an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA-positive at baseline and the titer of one or more post-baseline samples was at least 4-fold greater (i.e., ≥ 0.60 titer units) than the titer of the baseline sample (treatment-enhanced ADA response).
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With Anti-Drug Antibodies to Emicizumab at Any Time Post-Baseline During the Study | 1 | 1 |
The levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold.
| Participants | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| Number of Participants With De Novo Development of Anti-Factor VIII (FVIII) Antibodies | 0 | 0 |
The number of bleeds over the efficacy period was assessed as an ABR using a negative binomial (NB) regression model, which accounts for different follow-up times. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
| bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| Treated Bleeds | 1.9 (1.22 to 3.02) |
| All Bleeds | 2.9 (1.97 to 4.17) |
| Treated Spontaneous Bleeds | 0.5 (0.26 to 1.00) |
| Treated Joint Bleeds | 1.2 (0.69 to 2.17) |
| Treated Target Joint Bleeds | 0.5 (0.24 to 1.26) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
| bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| Treated Bleeds | 2.0 (0.25 to 7.28) |
| All Bleeds | 3.0 (0.63 to 8.82) |
| Treated Spontaneous Bleeds | 0.7 (0.00 to 4.95) |
| Treated Joint Bleeds | 1.3 (0.07 to 6.11) |
| Treated Target Joint Bleeds | 0.6 (0.00 to 4.77) |
The number of bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. All bleeds included both treated and non-treated bleeds. Treated spontaneous bleeds: treated bleeds with no known contributing factor (e.g., trauma, surgery). Treated joint bleeds: treated bleeds in a joint associated with unusual sensation (aura) in a joint, in combination with another symptom: swelling/warmth, pain/decreased range of motion (RoM), or difficulty moving the joint. Treated target joint bleeds: treated joint bleeds in a target joint, defined as a joint in which greater than or equal to (≥) 3 treated joint bleeds occurred during the last 24 weeks prior to study entry. For all types of bleeds: the 72-hour rule was implemented, and bleeds due to surgery/procedure and bleeds after up-titration or change of dosing regimen were excluded.
| bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| Treated Bleeds | 0.6 (0.20 to 2.20) |
| All Bleeds | 1.2 (0.60 to 3.78) |
| Treated Spontaneous Bleeds | 0.0 (0.00 to 0.59) |
| Treated Joint Bleeds | 0.3 (0.00 to 1.22) |
| Treated Target Joint Bleeds | 0.0 (0.00 to 0.20) |
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| Treated bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| 1 to 12 Weeks | 2.3 (0.35 to 7.75) |
| 13 to 24 Weeks | 2.5 (0.43 to 8.08) |
| 25 to 36 Weeks | 1.5 (0.11 to 6.40) |
| 37 to 48 Weeks | 1.9 (0.23 to 7.14) |
| 49 to 60 Weeks | 1.3 (0.06 to 6.01) |
| 61 to 72 Weeks | 2.7 (0.48 to 8.25) |
| 73 to 84 Weeks | 1.1 (0.04 to 5.72) |
| 85 to 96 Weeks | 1.4 (0.10 to 6.33) |
| 97 to 108 Weeks | 2.0 (0.23 to 7.19) |
| 109 to 120 Weeks | 1.4 (0.08 to 6.22) |
| 121 to 132 Weeks | 1.8 (0.18 to 6.87) |
| 133 to 144 Weeks | 1.0 (0.02 to 5.55) |
| 145 to 156 Weeks | 1.6 (0.13 to 6.55) |
| 157 to 168 Weeks | 2.0 (0.23 to 7.19) |
| 169 to 180 Weeks | 2.1 (0.26 to 7.34) |
| 181 to 192 Weeks | 1.3 (0.07 to 6.09) |
| 193 to 204 Weeks | 1.7 (0.15 to 6.73) |
| 205 to 216 Weeks | 1.4 (0.10 to 6.33) |
| 217 to 228 Weeks | 1.2 (0.05 to 5.93) |
| 229 to 240 Weeks | 1.0 (0.02 to 5.51) |
| 241 to 252 Weeks | 2.4 (0.40 to 7.92) |
| 253 to 264 Weeks | 2.6 (0.46 to 8.17) |
The number of treated bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated bleeds: a bleed for which coagulation factors were administered. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| Treated bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 4.35) |
| 13 to 24 Weeks | 0.0 (0.00 to 4.35) |
| 25 to 36 Weeks | 0.0 (0.00 to 0.00) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 0.00) |
| 61 to 72 Weeks | 0.0 (0.00 to 2.17) |
| 73 to 84 Weeks | 0.0 (0.00 to 0.00) |
| 85 to 96 Weeks | 0.0 (0.00 to 0.00) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 0.00) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 4.35) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
| 241 to 252 Weeks | 0.0 (0.00 to 4.35) |
| 253 to 264 Weeks | 4.3 (0.00 to 4.35) |
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| All bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| 1 to 12 Weeks | 5.1 (1.67 to 11.80) |
| 13 to 24 Weeks | 4.0 (1.11 to 10.29) |
| 25 to 36 Weeks | 3.1 (0.66 to 8.90) |
| 37 to 48 Weeks | 2.5 (0.42 to 8.03) |
| 49 to 60 Weeks | 2.2 (0.30 to 7.50) |
| 61 to 72 Weeks | 3.5 (0.85 to 9.52) |
| 73 to 84 Weeks | 1.8 (0.17 to 6.85) |
| 85 to 96 Weeks | 2.0 (0.24 to 7.21) |
| 97 to 108 Weeks | 2.4 (0.37 to 7.81) |
| 109 to 120 Weeks | 1.6 (0.13 to 6.55) |
| 121 to 132 Weeks | 2.2 (0.30 to 7.50) |
| 133 to 144 Weeks | 1.2 (0.05 to 5.89) |
| 145 to 156 Weeks | 2.0 (0.23 to 7.19) |
| 157 to 168 Weeks | 2.0 (0.23 to 7.19) |
| 169 to 180 Weeks | 2.3 (0.33 to 7.66) |
| 181 to 192 Weeks | 1.7 (0.17 to 6.81) |
| 193 to 204 Weeks | 1.9 (0.22 to 7.12) |
| 205 to 216 Weeks | 1.4 (0.10 to 6.33) |
| 217 to 228 Weeks | 1.7 (0.15 to 6.73) |
| 229 to 240 Weeks | 1.0 (0.02 to 5.51) |
| 241 to 252 Weeks | 2.4 (0.40 to 7.92) |
| 253 to 264 Weeks | 2.6 (0.46 to 8.17) |
The number of all bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. All bleeds included both treated bleeds (with coagulation factors) and non-treated bleeds. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| All bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 8.70) |
| 13 to 24 Weeks | 4.3 (0.00 to 4.35) |
| 25 to 36 Weeks | 0.0 (0.00 to 4.35) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 4.35) |
| 61 to 72 Weeks | 0.0 (0.00 to 4.35) |
| 73 to 84 Weeks | 0.0 (0.00 to 4.35) |
| 85 to 96 Weeks | 0.0 (0.00 to 2.17) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 4.35) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 4.35) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
| 241 to 252 Weeks | 0.0 (0.00 to 4.35) |
| 253 to 264 Weeks | 4.3 (0.00 to 4.35) |
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| Treated spontaneous bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| 1 to 12 Weeks | 0.4 (0.00 to 4.35) |
| 13 to 24 Weeks | 1.0 (0.02 to 5.49) |
| 25 to 36 Weeks | 0.1 (0.00 to 3.93) |
| 37 to 48 Weeks | 0.0 (0 to 3.69) |
| 49 to 60 Weeks | 0.3 (0.00 to 4.38) |
| 61 to 72 Weeks | 0.2 (0.00 to 4.18) |
| 73 to 84 Weeks | 0.1 (0.00 to 3.97) |
| 85 to 96 Weeks | 0.0 (0 to 3.69) |
| 97 to 108 Weeks | 0.2 (0.00 to 4.09) |
| 109 to 120 Weeks | 0.4 (0.00 to 4.48) |
| 121 to 132 Weeks | 0.4 (0.00 to 4.48) |
| 133 to 144 Weeks | 0.4 (0.00 to 4.48) |
| 145 to 156 Weeks | 1.0 (0.02 to 5.55) |
| 157 to 168 Weeks | 1.8 (0.18 to 6.87) |
| 169 to 180 Weeks | 0.0 (0 to 3.69) |
| 181 to 192 Weeks | 0.0 (0 to 3.69) |
| 193 to 204 Weeks | 0.7 (0.01 to 5.09) |
| 205 to 216 Weeks | 0.5 (0.00 to 4.64) |
| 217 to 228 Weeks | 0.0 (0 to 3.69) |
| 229 to 240 Weeks | 0.2 (0.00 to 4.18) |
| 241 to 252 Weeks | 0.8 (0.01 to 5.25) |
| 253 to 264 Weeks | 0.0 (0 to 3.69) |
The number of treated spontaneous bleeds over the efficacy period was calculated as: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. Treated spontaneous bleeds were defined as treated (with coagulation factors) bleeds with no known contributing factor (e.g., trauma, surgery). The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded. For participants with dose up-titration or a change in emicizumab dosing regimen (after implementation of protocol v5), the efficacy period ended the day before the first day on the up-titrated dose or changed dosing regimen.
| Treated spontaneous bleeds per year | Emicizumab: Expansion Cohort |
|---|---|
| 1 to 12 Weeks | 0.0 (0.00 to 0.00) |
| 13 to 24 Weeks | 0.0 (0.00 to 0.00) |
| 25 to 36 Weeks | 0.0 (0.00 to 0.00) |
| 37 to 48 Weeks | 0.0 (0.00 to 0.00) |
| 49 to 60 Weeks | 0.0 (0.00 to 0.00) |
| 61 to 72 Weeks | 0.0 (0.00 to 0.00) |
| 73 to 84 Weeks | 0.0 (0.00 to 0.00) |
| 85 to 96 Weeks | 0.0 (0.00 to 0.00) |
| 97 to 108 Weeks | 0.0 (0.00 to 0.00) |
| 109 to 120 Weeks | 0.0 (0.00 to 0.00) |
| 121 to 132 Weeks | 0.0 (0.00 to 0.00) |
| 133 to 144 Weeks | 0.0 (0.00 to 0.00) |
| 145 to 156 Weeks | 0.0 (0.00 to 0.00) |
| 157 to 168 Weeks | 0.0 (0.00 to 0.00) |
| 169 to 180 Weeks | 0.0 (0.00 to 0.00) |
| 181 to 192 Weeks | 0.0 (0.00 to 0.00) |
| 193 to 204 Weeks | 0.0 (0.00 to 0.00) |
| 205 to 216 Weeks | 0.0 (0.00 to 0.00) |
| 217 to 228 Weeks | 0.0 (0.00 to 0.00) |
| 229 to 240 Weeks | 0.0 (0.00 to 0.00) |
| 241 to 252 Weeks | 0.0 (0.00 to 0.00) |
| 253 to 264 Weeks | 0.0 (0.00 to 0.00) |
Collected over From Baseline to study completion, dose up-titration, or change of dosing regimen, whichever occurred first (up to 5 years, 5 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Emicizumab: PK Run-In Cohort | 0/7 (0%) | 2/7 (28.6%) | 7/7 (100%) |
| Emicizumab: Expansion Cohort | 0/41 (0%) | 8/41 (19.5%) | 37/41 (90.2%) |
| Event | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| CHOLELITHIASIS OBSTRUCTIVEHepatobiliary disorders | 1/7 | 0/41 |
| HYPERTENSIONVascular disorders | 1/7 | 0/41 |
| ATRIAL FIBRILLATIONCardiac disorders | 0/7 | 1/41 |
| TOOTHACHEGastrointestinal disorders | 0/7 | 1/41 |
| CELLULITISInfections and infestations | 0/7 | 1/41 |
| HEAD INJURYInjury, poisoning and procedural complications | 0/7 | 1/41 |
| RHABDOMYOLYSISMusculoskeletal and connective tissue disorders | 0/7 | 1/41 |
| BLADDER NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 1/41 |
| DIFFUSE LARGE B-CELL LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 1/41 |
| TUMOUR COMPRESSIONNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 1/41 |
| Event | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort |
|---|---|---|
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 4/7 | 17/41 |
| HEADACHENervous system disorders | 4/7 | 12/41 |
| OSTEOARTHRITISMusculoskeletal and connective tissue disorders | 3/7 | 1/41 |
| SYNOVITISMusculoskeletal and connective tissue disorders | 3/7 | 2/41 |
| NASOPHARYNGITISInfections and infestations | 0/7 | 14/41 |
| ABDOMINAL PAINGastrointestinal disorders | 2/7 | 2/41 |
| ODYNOPHAGIAGastrointestinal disorders | 2/7 | 0/41 |
| EAR INFECTIONInfections and infestations | 2/7 | 0/41 |
| PHARYNGITISInfections and infestations | 2/7 | 0/41 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 2/7 | 3/41 |
| Age, Categorical(Participants) | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort | Total |
|---|---|---|---|
| <=18 years | 1 | 3 | 4 |
| Between 18 and 65 years | 6 | 35 | 41 |
| >=65 years | 0 | 3 | 3 |
| Sex: Female, Male(Participants) | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 7 | 41 | 48 |
| Ethnicity (NIH/OMB)(Participants) | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 6 | 38 | 44 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 8 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 5 | 31 | 36 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Number of Participants with 0, 1, or >1 Target Joints in the Last 24 Weeks Prior to Study Entry(Participants) | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort | Total |
|---|---|---|---|
| 0 Target Joints | 1 | 16 | 17 |
| 1 Target Joint | 2 | 8 | 10 |
| >1 Target Joints | 4 | 17 | 21 |
| Number of Participants by Hemophilia A Severity at Baseline(Participants) | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort | Total |
|---|---|---|---|
| Mild | 0 | 1 | 1 |
| Moderate | 0 | 0 | 0 |
| Severe | 7 | 40 | 47 |
| Number of Participants by Factor VIII Inhibitor Status at Baseline(Participants) | Emicizumab: PK Run-In Cohort | Emicizumab: Expansion Cohort | Total |
|---|---|---|---|
| Factor VIII Inhibitor Positive | 3 | 5 | 8 |
| Factor VIII Inhibitor Negative | 4 | 36 | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2017 to primary completion in Dec 2017, 10 months.
Results were first posted in Dec 2018, 1 year after primary completion.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 10 months is below that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emicizumab